Zydus Lifesciences received tentative USFDA approval for its generic Ibrutinib tablets, used to treat various blood cancers like CLL/SLL and Waldenstrom's macroglobulinemia. The tablets, available in 140 mg, 280 mg, and 420 mg strengths, will be manufactured in Ahmedabad. Ibrutinib tablets had significant US sales, reaching USD 2148.9 million annually.